Correction to Lancet Infect Dis 2024; published online April 30. https://doi.org/10.1016/S1473-3099(24)00215-9

No authors listed

Published Erratum

No authors listed. Lancet Infect Dis. 2024 Jul.

. 2024 Jul;24(7):e419.

doi: 10.1016/S1473-3099(24)00355-4. Epub 2024 May 23.

No abstract available

Erratum for

Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
Ares-Gómez S, Mallah N, Santiago-Pérez MI, Pardo-Seco J, Pérez-Martínez O, Otero-Barrós MT, Suárez-Gaiche N, Kramer R, Jin J, Platero-Alonso L, Alvárez-Gil RM, Ces-Ozores OM, Nartallo-Penas V, Mirás-Carballal S, Piñeiro-Sotelo M, Malvar-Pintos A, González-Pérez JM, Rodríguez-Tenreiro-Sánchez C, Rivero-Calle I, Salas A, Durán-Parrondo C, Martinón-Torres F; NIRSE-GAL study group. Ares-Gómez S, et al. Lancet Infect Dis. 2024 Aug;24(8):817-828. doi: 10.1016/S1473-3099(24)00215-9. Epub 2024 Apr 30. Lancet Infect Dis. 2024. PMID: 38701823